Weight-loss drugs, which have taken the world by storm, could soon become cheaper and more widely accessible, with the patent for semaglutide — sold under the brand names Wegovy and Ozempic — set to expire in several major markets in early 2026.
Semaglutide is part of a group of drugs that have become central in the fight against obesity and metabolic diseases, with one study estimating that their universal availability could reduce global obesity prevalence by 20% and save 28 million lives over a period of five years. But high prices and intellectual property barriers have left the treatment out of reach to most, especially in low- and middle-income countries.
That is likely to change next year, with the patent expiry on semaglutide sparking a race to manufacture copycat — and significantly more affordable — versions of the drug in countries such as India and China.
This article is free to read – just register or sign in
Access news, newsletters, events and more.
Join usSign in
Printing articles to share with others is a breach of our terms and conditions and copyright policy. Please use the sharing options on the left side of the article. Devex Pro members may share up to 10 articles per month using the Pro share tool ( ).
